Company Filing History:
Years Active: 2024
Title: The Innovations of Yun Song
Introduction
Yun Song is an accomplished inventor based in South San Francisco, CA. He has made significant contributions to the field of immunotherapy, particularly through his innovative work on chimeric antigen receptors.
Latest Patents
Yun Song holds a patent for a groundbreaking invention titled "ROR1 targeting chimeric antigen receptor." This patent relates to polynucleotides encoding a chimeric polypeptide that includes a c-Jun polypeptide, a ROR1-binding protein, and a truncated EGF receptor. The invention also encompasses cells, such as T cells, that express CARs comprising a ROR1-binding protein and overexpress a c-Jun polypeptide. The overexpression of c-Jun in CAR T cells is designed to improve their properties, particularly in reducing or preventing exhaustion.
Career Highlights
Yun Song is currently employed at Lyell Immunopharma, Inc., where he continues to advance his research in the field of immunotherapy. His work is pivotal in developing therapies that harness the power of the immune system to combat cancer.
Collaborations
Yun collaborates with talented colleagues, including Spencer Park and Queenie Vong, who contribute to the innovative environment at Lyell Immunopharma.
Conclusion
Yun Song's contributions to the field of immunotherapy through his patent on ROR1 targeting chimeric antigen receptors exemplify his commitment to advancing medical science. His work has the potential to significantly impact cancer treatment and improve patient outcomes.